Human papillomavirus, human immunodeficiency virus and immunosuppression

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Denny, Lynette A ^a   Franceschi, Silvia ^b   de Sanjosé, Silvia ^c,d   Heard, Isabelle ^e   Moscicki, Anna Barbara ^f   Palefsky, Joel ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anal cancer; Cervical cancer; HIV; HPV; Hpv vaccination; Immunosuppression; Male circumcision; Perinatal transmission; Prevention

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; CANCER REGISTRY; CANCER SCREENING; CELLULAR IMMUNITY; CIRCUMCISION; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION SENSITIVITY; MALE HOMOSEXUAL; META ANALYSIS (TOPIC); MIXED INFECTION; PAPILLOMAVIRUS INFECTION; PERINATAL PERIOD; PRECURSOR; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS;

EID: 84873059108     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.045     Document Type: Review

References (45)

1. [1993] revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults MMWR Recommit Rep 1992; 41:1-19
2. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008 b;17:545-54.
3. Harris TG, Burk RB, Palefsky JM, Massed LS, Bang JY, Anastos K, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005;293: 1471-6.
4. Singh D, Anastos K, Hoover D, Burk R, Shi Q, Ngendahayo L, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009;199(12):1851-61.
5. Denny L, Boa R, Williamson AL, Allan B, Hardie D, Ress S, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women. Obstet Gynecol 2008;111(6):1380-7.
6. Clifford GM, Goncalves MA, Franceschi S, HPV, HIV study group. Human papillomavirus types among women infected with HIV: a meta-analyisis. AIDS 2006;20(18):2337-44.
7. Veldhuizen NJ, Braunstein SL, Vyankandondera J, Ingabire C, Ntirushwa J, Kestelyn E. The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda. BMC Infect Dis 2011;11:333.
8. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009;4(1):52-6.
9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.
10. Parkin DM, Louie KS, Clifford G. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine 2008;26(SUPPL 12):M1-16.
11. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA., Risk of human papillomavirus-associated cancers among persons with AIDS. 2009;101;16: 1120-30.
12. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D. HIV infection, immunodeficiency, viral replication and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20(12):2551-9.
13. Minkoff H, Zhong Y, Burk RD, Palefsky JM, Xue X, Heather Watts D, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. JID 2010;201:681-90.
14. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
15. De Vuyst H, Gichangi PB, Estambale B, Njuguna E, Franceschi S, Temmerman M. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer 2008;122:244-6.
16. Odida M, Sandin S, Mirembe F, Kleter B, Quint W, Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study. Infect Agent Cancer 2011;6:8.
17. De Vuyst H, Ndirangu G, Moodley M, Tenet V, Estambale B, Meijer CJLM, et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer 2011 Sep 29, http://dx.doi.org/10.1002/ijc.26470.
18. Naucler P, da Costa FM, Da Costa JL, Ljungberg O, Bugalho A, Dilner J. Human papillomavirus type-specific risk of cervical cancer in a population with high human immunodeficiency virus prevalences: case - control study. J Gen Virol 2011;92:2784-91.
19. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JS, et al. Prevalence and distribution of HPV genotypes among HIVinfected women in Zambia. Br J Cancer 2007;96:1480-3.
20. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
21. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:1120-30.
22. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005;32(SUPPL 1):S82-90.
23. Chin-Hong PV, Husnik M, Cranston RD, Colfax G, Buchbinder S, Da Costa M, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009;23(9):1135-42.
24. Smith JS, Moses S, Hudgens M, Parker CB, Agot K, Maclean I, et al. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis 2010;201(11):1677-85.
25. Smith-McCune KK, Shiboski S, Chirenje MZ, Magure T, Tuveson J, Ma Y, et al. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One 2010;5(4).
26. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage III GR, Oleske J, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health 2007;97:1047-52.
27. Nachman S, Chernoff M, Gona P, Van Dyke RB, Dankner WM, Seage III GR, et al. Incidence of non infectious conditions in perinatally HIV infected children and adolescents in the HAART Era. Archiv Pediatrc Adolesc Med 2009;163(2):164-71.
28. Magalhaes MG, Bueno DF, Serra E, Goncalves R. Oral manifestations of HIV positive children. Clin Pediatr Dent 2001;25:103-6.
29. Pinheiro RS, de Franca TR, Rocha B, Ferreira DC, Ribeiro CM, Cavalcanti SM, et al. HPV co-infection in the oral cavity of HIV-infected children. J Clin Path 2011;64(12):1083-7.
30. Levin M, Moscicki A, Song L, Fenton T, Meyer III WA, Read JS, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (Types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immun Defic Syndr 2010;55(2):197-204.
31. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124(7):1626-36.
32. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124(10):2375-83.
33. Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 2006;76(8):715-7.
34. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101(2): 281-8.
35. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005;19(13): 1407-14.
36. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92(18):1500-10.
37. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103(9):753-62.
38. Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009;52(2): 239-47.
39. Darragh TM, Winkler B. Anal cancer and cervical cancer screening: Key differences. Cancer Cytopathol 2011;119(1):5-19.
40. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;281(19):1822-9.
41. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV -16/18 ASO4- adjuvanted vaccine in HIV positive women in South Africa. Abstract no.599. In: AORTIC 7th International Conference. 2011.
42. Siegfried N, Muller M, Deeks JJ, Volmink J. Male Circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009;(2). CD003362.
43. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infection and syphilis. N Engl J Med 2009;360:1298-309.
44. Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and Neisseria gonorrheae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HPV prevention. Sex Trans Infect 2009;85:116-20.
45. Larke N, Thomas SL, dos Santos SI, Weiss HA. Male circumcision and human papillomavirus infection in men: A systematic review and meta-analysis. J Infect Dis 2011;204:1375-90